Hepion pharmaceuticals announces usan selection of “rencofilstat” as nonproprietary name for crv431

Edison, n.j., jan. 06, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and other liver diseases, today announced the united states adopted names (“usan”) council has adopted the nonproprietary name “rencofilstat” for the company's lead drug candidate, crv431.
HEPA Ratings Summary
HEPA Quant Ranking